upgraded at Dahlman from Hold to Buy, Dahlman Rose said. $14 price target. Mountain Pass should deliver a large production ramp.
upgraded at BofA/Merrill from Neutral to Buy, Bank of America/Merrill Lynch said. $32 price target. Company can continue to diversify and expand its business.
downgraded at JP Morgan from Neutral to Underweight, JP Morgan said. $40 price target. Oral Remodulin received a negative ruling from the FDA.
United Therapeutics downgraded at BMO from Outperform to Market Perform, BMO Capital said. $50 price target. New uncertainty around oral treprostinil.
upgraded at Goldman from Sell to Buy, Goldman Sachs said. $110 price target. Prices have firmed in Latin America.
STOCK COMMENTS / EPS CHANGES
(AAPL - Get Report)
estimates, target raised at Canaccord. Shares of AAPL now seen reaching $800, according to Canaccord Genuity said. Estimates also increased, given the new product launches. Buy rating.
estimates, target reduced at BMO. ALTR estimates were cut through 2013, BMO Capital said. Company is seeing lower sales. Outperform rating and new $38 price target.
(AMGN - Get Report)
estimates, target increased at BMO. AMGN estimates were raised through 2013, BMO Capital said. Company is cutting costs and buying back more stock. Market Perform rating and new $83 price target.
added to US Focus List at Credit Suisse. Company can expand its margins over the coming quarters.
estimates, target cut at Credit Suisse. Shares of BRCM now seen reaching $45, according to Credit Suisse. Estimates also reduced, as the company is seeing lower sales. Outperform rating.
numbers raised at Oppenheimer. Shares of CNC now seen reaching $48, Oppenheimer said. Estimates also raised on third quarter earnings. Outperform rating.
(COH - Get Report)
numbers raised at UBS. Shares of COH now seen reaching $58, UBS said. Estimates also increased as F1Q trends improve. Neutral rating.
(DD - Get Report)
numbers cut at UBS. Shares of DD now seen reaching $52, UBS said. Estimates also lowered on material 3Q EPS miss. Neutral rating.
estimates, target boosted at Credit Suisse. Shares of GILD now seen reaching $65, according to Credit Suisse. Estimates also upped, given higher product sales. Neutral rating.
Gilead Sciences numbers raised at Jefferies. Shares of GILD now seen reaching $59, Jefferies said. Estimates also raised on HCV pipeline. Hold rating.
added to US Focus List at Credit Suisse. HIG was added to the US focus list, according to Credit Suisse. See upside to capital return expectations.
Kansas City Southern
added to US Focus List at Credit Suisse. KSU was placed on the US focus list, Credit Suisse said. Company can continue to grow faster than consensus expectations.
estimates trimmed at UBS through 2013, UBS said. 3Q outlook weaker than expected. Buy rating and $100 price target.
numbers lowered at Oppenheimer. Shares of NFLX now seen reaching $80, Oppenheimer said. Estimates also lowered on weak subs and guidance. Outperform rating.
Netflix estimates, target cut at BofA/Merrill. Shares of NFLX now seen reaching $60, according to Bank of America/Merrill Lynch said. International segment will likely continue to lose money for the next few years. Underperform rating.
Netflix target cut at Citigroup. NFLX target lowered to $100, Citigroup said. Q3 miss, but willing to look through forecasting errors. Buy rating.
numbers lowered at Sterne Agee. Shares of NSC now seen reaching $81, according to Sterne Agee. Estimates also cut, given a reduced coal outlook. Buy rating.
estimates, target increased at Sterne Agee. TRV estimates were raised through 2014, Sterne Agee said. Company is seeing a higher reserve release and lower loss ratio. Neutral rating and new $77 price target.